<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[business operations and pharmaceutical company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/business+operations+and+pharmaceutical+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to business operations and pharmaceutical company]]></description>
	<s:counts start="0" returned="20" found="62" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Covance Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-355411.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. We'll take our first question today from Mr. Greg Bolan with Wells Fargo. Greg Bolan - Wells Fargo Just thinking about Early Development activity these days and I realize this is an overly simplistic analogy, but it would appear to me that pharma has been...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 22 Oct 2009 11:19:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wells+fargo+%2526+co..html"><![CDATA[Wells Fargo & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/covance+inc..html"><![CDATA[Covance Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/joe+herring+lumpy.html"><![CDATA[Joe Herring Lumpy]]></category>
		<category domain="http://resources.bnet.com/topic/managed+hosting.html"><![CDATA[Managed Hosting]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WFC</category>
		<category domain="tickers">CVD,WFC</category>
	</item>
	<item>
		<title><![CDATA[Simcere Pharmaceutical Group Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-332582.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Shaojing Tong. Shaojing Tong - Bank of America-Merrill Lynch I just want to focus on this brand generic portfolio, whose sales fall substantially lower than the average normal level. You explained somewhat, but my focus was beyond...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 18 Aug 2009 10:42:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
	</item>
	<item>
		<title><![CDATA[Maximizing Value In Outsourcing Services]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1123511]]></link>
		<description><![CDATA[The pharmaceutical industry is, without a doubt, feeling the crunch of skyrocketing costs, lackluster pipelines, and drug safety issues. Clinical professionals need to do more with less, while still maintaining the highest levels of quality. Many companies are choosing Contract Research Organizations CROs as a cost-effective strategy to outsource services...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Sun, 15 Mar 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/genetic+engineering.html"><![CDATA[Genetic Engineering]]></category>
		<category domain="http://resources.bnet.com/topic/outsource.html"><![CDATA[Outsource]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/genetic+engineering+%2526+biotechnology+news.html"><![CDATA[Genetic Engineering & Biotechnology News]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/managed+hosting.html"><![CDATA[Managed Hosting]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
	</item>
	<item>
		<title><![CDATA[PAREXEL International Corporation F2Q09 (Qtr End 12/31/08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-264368.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions We have the first question from the line of Todd Van Fleet, First Analysis. Please go ahead. Todd Van Fleet &#8211; First Analysis Good morning, guys. I&#8217;d just ask you three quick ones if I could. First, Joe, I guess with respect to you decision...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 27 Jan 2009 11:36:14 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/managed+hosting.html"><![CDATA[Managed Hosting]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/parexel+international+corp..html"><![CDATA[PAREXEL International Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PRXL</category>
		<category domain="tickers">PRXL</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Sanofi Axes Reps, Glaxo Fights Patent Office, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000464/pharma-roundup-sanofi-axes-reps-glaxo-fights-patent-office-and-more/]]></link>
		<description><![CDATA[Sanofi-Aventis cuts 650 sales reps, Glaxo heads to court, FDA deals Roche a setback, Deerfield may purchase all of Nitromed. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Dec 2008 16:48:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent And Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/ipo.html"><![CDATA[IPO]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000434/pharma-roundup-astrazeneca-and-teva-mend-fences-barbara-ryans-ma-speculation-and-more/]]></link>
		<description><![CDATA[AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 25 Nov 2008 17:50:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/m%2526a.html"><![CDATA[M&A]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/indonesia.html"><![CDATA[Indonesia]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">AZN,PFE</category>
	</item>
	<item>
		<title><![CDATA[Obama Already Turning Into a Nightmare for Big Pharma]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000371/obama-already-turning-into-a-nightmare-for-big-pharma/]]></link>
		<description><![CDATA[President Barack Obama's new chief of staff, Rahm Emanuel, is turning out to be Big Pharma's worse nightmare. He twice put out press releases backing the crusade of Peter Rost, the former Pfizer vp turned whistleblower, in favor of allowing drug reimportation from foreign countries to encourage price competition. (See...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 07 Nov 2008 08:36:53 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[American Oriental Announces Two Acquisitions]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F101432-american-oriental-announces-two-acquisitions%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 23 Oct 2008 05:35:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[Acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/hospital.html"><![CDATA[Hospital]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/american+oriental+bioengineering+inc..html"><![CDATA[American Oriental Bioengineering Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AOB</category>
		<category domain="tickers">AOB</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: AstraZeneca Wins Web Traffic, Genentech Wins "Best Employer," and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000284/pharma-roundup-astrazeneca-wins-web-traffic-genentech-wins-best-employer-and-more/]]></link>
		<description><![CDATA[AstraZeneca's Nexium is most-visited drug website, Genentech voted best place to work, fewer DDMAC warning letters over time, GSK execs talk research. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 10 Oct 2008 14:46:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">AZN,DNA</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer Re-Slices Organizational Pie, Lilly Dishes Out Zyprexa Settlement, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000268/pharma-roundup-pfizer-re-slices-organizational-pie-lilly-dishes-out-zyprexa-settlement-and-more/]]></link>
		<description><![CDATA[Pfizer reorganizes; Lilly to pay $62 million fine over Zyprexa; biotech losing talent to clean tech; Consumer Reports blacklists 20 drugs for seniors by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 07 Oct 2008 15:11:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/clean+technology.html"><![CDATA[Clean Technology]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Merck Gets Transparent, Pfizer Mulls Layoffs, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000240/pharma-roundup-merck-gets-transparent-pfizer-mulls-layoffs-and-more/]]></link>
		<description><![CDATA[Merck latest to announce transparency policies -- As the Physician Payments Sunshine Act approaches Congressional approval, Merck has announced a plan to publicize the grants they offer medical organizations and speakers. Earlier this week, Lilly made a similar promise, and several other pharma companies have recently retooled their disclosure policies....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 25 Sep 2008 18:30:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/boehringer+ingelheim.html"><![CDATA[Boehringer Ingelheim]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">MRK,PFE</category>
	</item>
	<item>
		<title><![CDATA[The 100 Best Companies for Work-Life Balance]]></title>
		<link><![CDATA[http://blogs.bnet.com/teamwork/?p=417]]></link>
		<description><![CDATA[If you value work-life balance, don't miss Working Mother magazine's 2008 list of the 100 best companies.Â  Says Carol Evans, CEO of Working Mother Media:  The 100 Best Companies set the standard for work-life excellence.Â  In the midst of economic uncertainty these companies continue to embrace  work-life as...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 24 Sep 2008 10:26:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[Financial]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/consulting.html"><![CDATA[Consulting]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/cc+holland.html"><![CDATA[CC Holland]]></category>
	</item>
	<item>
		<title><![CDATA[Johns Hopkins in Pharma Funding Flap]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/2008/08/05/johns-hopkins-in-pharma-funding-flap/]]></link>
		<description><![CDATA[Is Johns Hopkins University Medical School offering to endorse drug company "educational" materials for money? That was the allegation made last week by Daniel Carlat, a blogger and psychiatrist in private practice.    Johns Hopkins, naturally, denies the claim.    Carlat says Johns Hopkins is offering...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 05 Aug 2008 06:46:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/certification.html"><![CDATA[Certification]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/carlat.html"><![CDATA[Carlat]]></category>
		<category domain="http://resources.bnet.com/topic/cme.html"><![CDATA[CME]]></category>
		<category domain="http://resources.bnet.com/topic/cme+event.html"><![CDATA[CME Event]]></category>
		<category domain="http://resources.bnet.com/topic/quality.html"><![CDATA[Quality]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Outsourcing: Industry Can't Win for Losing]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000147/pharma-outsourcing-industry-cant-win-for-losing/]]></link>
		<description><![CDATA[Given all the trauma the drug industry is currently going through, you can hardly blame executives for cutting costs wherever they can. Unsurprisingly, outsourcing is a big part of Big Pharma's repair toolkit these days. Pfizer, for instance, says that 17 percent of its manufacturing and active ingredients are currently...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 28 Jul 2008 06:48:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/outsource.html"><![CDATA[Outsource]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[High Performance In Sight: Pharmaceutical Company Saves Money By Streamlining IT Infrastructure]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1181163]]></link>
		<description><![CDATA[To sustain revenues in a competitive market and invest more aggressively in research and development, one of the world's largest pharmaceutical companies made a strategic decision to reduce US$100 million from its IT budget. IT standardization was the first item on the agenda. Accenture marshalled a team from Accenture Technology...]]></description>
		<s:doctype><![CDATA[Case studies]]></s:doctype>
		<pubDate>Wed, 23 Jul 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/it+infrastructure.html"><![CDATA[IT Infrastructure]]></category>
		<category domain="http://resources.bnet.com/topic/information+technology.html"><![CDATA[Information Technology]]></category>
		<category domain="http://resources.bnet.com/topic/accenture+ltd..html"><![CDATA[Accenture Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/high-performance.html"><![CDATA[High-performance]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/itil.html"><![CDATA[ITIL]]></category>
		<category domain="http://resources.bnet.com/topic/process+improvement.html"><![CDATA[Process Improvement]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/it+services.html"><![CDATA[It Services]]></category>
		<category domain="http://resources.bnet.com/topic/quality.html"><![CDATA[Quality]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACN</category>
		<category domain="tickers">ACN</category>
	</item>
	<item>
		<title><![CDATA[Pharma Is Whacking R&D, Too -- Or Is It?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10006/pharma-is-whacking-rd-too-or-is-it/]]></link>
		<description><![CDATA[The variety of woes afflicting Big Pharma have led to a spate of well-publicized layoffs, mostly among sales forces -- 42,000 since the beginning of 2007, according to one count. Yesterday, Cole Werber at the In Vivo Blog highlighted yet another foreboding statistic: Drugmakers are also starting to trim R&D...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sat, 12 Apr 2008 12:57:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/phrma.html"><![CDATA[PhRMA]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/werber.html"><![CDATA[Werber]]></category>
	</item>
	<item>
		<title><![CDATA[The Changing Face Of R&D In The Future Pharmaceutical Landscape]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=932331]]></link>
		<description><![CDATA[The global pharmaceutical industry has generated strong sales and revenue growth for much of the second half of the twentieth century. Over the 1996 - 2006 period, sales for U.S. firms, which increasingly dominate the global industry, rose from $102 billion to $276 billion while their R&D spending rose from...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 31 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/deloitte+touche+tohmatsu.html"><![CDATA[Deloitte Touche Tohmatsu]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
	</item>
	<item>
		<title><![CDATA[How Unpopular Is Big Business?]]></title>
		<link><![CDATA[http://blogs.bnet.com/intercom/?p=1517]]></link>
		<description><![CDATA[When Gallup asked Americans if the earth revolves around the sun, 79% said yes. Shocked that 21% disagreed? That lack of general knowledge may be alarming, but for folks in business it might be more shocking to know that more Americans believe big business is untrustworthy than  have a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 16 Jan 2008 11:04:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/jessica+stillman.html"><![CDATA[Jessica Stillman]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/food+%2526+beverage.html"><![CDATA[Food & Beverage]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/business.html"><![CDATA[Business]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/insurance+company.html"><![CDATA[Insurance Company]]></category>
	</item>
	<item>
		<title><![CDATA[The Eclinical Equation: Part 2 - Bridging Connections For Innovation]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=893417]]></link>
		<description><![CDATA[The pharmaceutical industry Pharma is at a critical point in its transition to a new model of drug development: making targeted medicines. The blockbuster model has served Pharma well, but it cannot address the challenges involved in predicting the safety and efficacy of new drugs, and developing treatments for patients...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Sun, 01 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/innovation.html"><![CDATA[Innovation]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma's New Worldview: Transforming R&d Through Emerging Markets]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=900479]]></link>
		<description><![CDATA[Like other industries, big Pharma has grown comfortable with certain offshore capabilities, such as manufacturing. But because they consider R&D such a defining capability, pharma companies have generally been hesitant to move R&D activities outside the firm - much less offshore. Squeezed by shareholder and payer demands, these companies are...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Fri, 01 Sep 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/offshore.html"><![CDATA[Offshore]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/emerging+market.html"><![CDATA[Emerging Market]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
	</item>
</channel>
</rss>
